MK-677 vs Ipamorelin

Reviewed by Gabriel Brocklesby · Last updated

Both are referenced as growth hormone secretagogues in performance and longevity clinic listings. MK-677 is orally active while ipamorelin is typically injectable. Compare clinic listings by service scope and monitoring protocols.

MK-677 and ipamorelin are often referenced in performance or longevity contexts. Clinics vary in how they position each option within protocols. Use this page to compare provider models and monitoring standards.

MK-677

A growth hormone secretagogue referenced in performance and longevity clinic listings. Not a peptide in the traditional sense.

Potential benefits

  • Often listed in performance-focused protocols.
  • Common in longevity clinic menus.

Considerations

  • Regulatory status varies.
  • Requires clinician-led assessment.
Best for: Comparing performance clinics and their monitoring models.

Ipamorelin

A GH secretagogue typically administered by injection in clinic protocols.

Potential benefits

  • Often paired with other secretagogues.
  • Common in longevity listings.

Considerations

  • Human evidence is limited.
  • Monitoring standards vary by clinic.
Best for: Evaluating hormone optimisation clinics and protocol transparency.
CategoryMK-677Ipamorelin
Directory contextInformational clinic and treatment comparison context.Informational clinic and treatment comparison context.
Common goalsCompare how clinics frame suitability, monitoring, and expected use cases.Compare how clinics frame suitability, monitoring, and expected use cases.
Guidance noteInformational listing only; suitability requires clinician review.Informational listing only; suitability requires clinician review.

Next step

Compare clinics offering these treatments

Use city pages and peptide-specific pages to move from general research into actual provider shortlists. That usually gives a better buying picture than comparing drug names alone.

Related clinics

FeaturedVerified

Menon Health

London, United Kingdom

Menon Health is a Mayfair-based peptide therapy clinic founded by Dr Mukil Menon, a GMC-registered physician and one of the first doctors to prescribe medical peptide therapy in the UK. Before establishing Menon Health, Dr Menon served as UK medical director at Koniver Wellness, launching the clinic at Soho House London. He continues to practise within the NHS alongside his private consultations, ensuring his protocols stay grounded in current medical standards. The clinic offers doctor-led, prescription-based peptide therapy alongside regenerative cell complex treatments, bloods and diagnostics, and IV therapy. All formulations are sourced from GMP-certified, EMA-regulated pharmacies and dispensed as pre-filled pens, vials, or multi-peptide syringes — Menon Health's approach to combining multiple peptides in a single dose is designed to improve precision and patient adherence. Based at 64 North Row in Mayfair, London, Menon Health serves patients across the UK, Europe, Canada, and the United States, with consultations available in person or remotely.

In personRemoteFrom £195Virtual consultations
View ProfileSend EnquiryCompare

Conclusion

Choose based on provider quality and monitoring rather than delivery format. Both are clinic-dependent and require clinician oversight.

Related peptide pages

US city pages

For clinics

Are you a clinic?

Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.